| HOME >> BIOLOGY >> TECHNOLOGY |
"WelChol may be a viable option for those who recognize the benefits of taking LDL cholesterol-lowering medications but are concerned about potential adverse side effects noted with other prescription options," adds Dr. Jones.
*For the purposes of this survey, those with "high cholesterol" were defined as U.S. adults (ages 20+) who have been diagnosed with high cholesterol and are doing something to manage their condition, including exercising regularly, changing diet, taking prescription medication, taking over-the-counter medication or eating cholesterol lowering food products.
About WelChol(R)
WelChol is indicated for LDL-C lowering and was approved by the U.S. Food and Drug Administration (FDA) for marketing in May 2000. WelChol is the top- selling branded drug in the bile acid sequestrants (BAS) class. WelChol is different from most other cholesterol-lowering drugs on the market because it is non-systemic, meaning that the body does not absorb it and it is eliminated without traveling to the liver or kidneys. Therefore, WelChol is not expected to have drug-drug interactions via the cytochrome P-450 pathway. Systemic medications, which include statins, fibrates, and cholesterol absorption inhibitors, are those that are absorbed from the intestine into the bloodstream and travel throughout the body, specifically to the liver and/or kidneys.
WelChol is a prescription drug indicated alone or in combination with a statin, as an adjunct to diet and exercise for the reduction of elevated LDL cholesterol in patients with primary hypercholesterolemia (Fredrickson Type IIa) when the response to diet and exercise has been inadequate. Liver- function monitoring is not required with WelChol when used as monotherapy, and in combination with a statin, no additional liver-function monitoring is required beyond that for the prescribed statin alone.
In clinica
'/>"/>
| SOURCE Daiichi Sankyo, Inc. Copyright©2007 PR Newswire. All rights reserved |